ReviewF1000prime reports2014
Recent advances in understanding schizophrenia.
Review in F1000prime reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Neuroretinal Alterations in Schizophrenia and Bipolar Disorder: An Updated Meta-analysis.Schizophrenia bulletin · 2024Pooled it
- Smartphone Apps to Support Coordinated Specialty Care for Prodromal and Early Course Schizophrenia Disorders: Systematic Review.Journal of medical Internet research · 2019Pooled it
- Trial
- Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment).Drug design, development and therapy · 2016Trial
- Retinal cytoarchitectural alterations across the psychosis spectrum and their correlates with cognition: a UK biobank nested case-control study.Molecular psychiatry · 2026Article
- Exploring the Intersection of Schizophrenia, Machine Learning, and Genomics: Scoping Review.JMIR bioinformatics and biotechnology · 2024Article
- A study of long-term GABA and high-energy phosphate alterations in the primary motor cortex using anodal tDCS andFrontiers in human neuroscience · 2024Article
- Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review.Neuropsychiatric disease and treatment · 2023Article
- An Observational Pilot Study using a Digital Phenotyping Approach in Patients with Major Depressive Disorder Treated with Trazodone.Frontiers in psychiatry · 2023Article
- Morphology of Anterior Cingulate Cortex and Its Relation to Schizophrenia.Journal of clinical medicine · 2022Article
- Quantifying Retinal Microvascular Morphology in Schizophrenia Using Swept-Source Optical Coherence Tomography Angiography.Schizophrenia bulletin · 2022Article
- Sex-Specific Changes in Choroid Vasculature Among Patients with Schizophrenia and Bipolar Disorder.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Early Detection and Prevention of Schizophrenic Psychosis-A Review.Brain sciences · 2021Review
- Multivariate relationships between peripheral inflammatory marker subtypes and cognitive and brain structural measures in psychosis.Molecular psychiatry · 2021Article
- Multisite schizophrenia classification by integrating structural magnetic resonance imaging data with polygenic risk score.NeuroImage. Clinical · 2021Article
- The Role of Brain Microvascular Endothelial Cell and Blood-Brain Barrier Dysfunction in Schizophrenia.Complex psychiatry · 2020Review
- Visual Cortical Alterations and their Association with Negative Symptoms in Antipsychotic-Naïve First Episode Psychosis.Psychiatry research · 2020Article
- Innate Immunity: A Common Denominator between Neurodegenerative and Neuropsychiatric Diseases.International journal of molecular sciences · 2020Review
- Assessing the potential of longitudinal smartphone based cognitive assessment in schizophrenia: A naturalistic pilot study.Schizophrenia research. Cognition · 2019Article
- The Importance of Structure and Connection for People Living With Schizophrenia: A 33-Year Outpatient Group Experience.Community mental health journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a highly disabling disorder whose causes remain to be better understood, and treatments have to be improved. However, several recent advances have been made in diagnosis, etiopathology, and treatment. Whereas reliability of diagnosis has improved with operational criteria, including Diagnostic and Statistical Manual of Mental Disorders, (DSM) Fifth Edition, validity of the disease boundaries remains unclear because of substantive overlaps with other psychotic disorders. Recent emphasis on dimensional approaches and translational bio-behavioral research domain criteria may eventually help move toward a neuroscience-based definition of schizophrenia. The etiology of schizophrenia is now thought to be multifactorial, with multiple small-effect and fewer large-effect susceptibility genes interacting with several environmental factors. These factors may lead to developmentally mediated alterations in neuroplasticity, manifesting in a cascade of neurotransmitter and circuit dysfunctions and impaired connectivity with an onset around early adolescence. Such etiopathological understanding has motivated a renewed search for novel pharmacological as well as psychotherapeutic targets. Addressing the core features of the illness, such as cognitive deficits and negative symptoms, and developing hypothesis-driven early interventions and preventive strategies are high-priority goals for the field. Schizophrenia is a severe, chronic mental disorder and is among the most disabling disorders in all of medicine. It is estimated by the National Institute of Mental Health (NIMH) that 2.4 million people over the age of 18 in the US suffer from schizophrenia. This illness typically begins in adolescence and derails the formative goals of school, family, and work, leading to considerable suffering and disability and reduced life expectancy by about 20 years. Treatment outcomes are variable, and some people are successfully treated and reintegrated (i.e. go back to work). Despite the effort of many experts in the field, however, schizophrenia remains a chronic relapsing and remitting disorder associated with significant impairments in social and vocational functioning and a shortened lifespan. Comprehensive treatment entails a multi-modal approach, including psychopharmacology, psychosocial interventions, and assistance with housing and financial sustenance. Research to date suggests a network of genetic, neural, behavioral, and environmental factors to be responsible for its development and course. This article aims to summarize and explain recent advancements in research on schizophrenia, to suggest how these recent discoveries may lead to a better understanding and possible further development of effective therapies, and to highlight the paradigm shifts that have taken place in our understanding of the diagnosis, etiopathology, and treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.